Fact CheckerSign in

NCT07146100Recruiting

Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection

Prospective, Open-label, Multicenter Long-term Follow-up Study to Evaluate the Durability of Virologic Response in Participants With Chronic Hepatitis B Previously Treated With AHB-137 Injection

Source: ClinicalTrials.gov · Last updated 18 Aug 2026

Brief summary (registry, in English)

This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.

Status (registry)
Recruiting
Study type
Observational
Enrollment
200 (estimated)
First submitted
19 Aug 2025
Start date
28 Aug 2025
Primary completion date
1 Jan 2028
Lead sponsor
Ausper Biopharma Co., Ltd.
Diseases
Hepatitis B
NCT number
NCT07146100

What you commit to

  • Study type: Observational
  • Planned participants: 200
  • From 28 Aug 2025 to the primary completion date, 1 Jan 2028
  • 28 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Participants who have/or are currently participating in another interventional clinical study since completing their treatment with AHB-137.

Other illness

  • Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.

Who the study is looking for

  • Capable of giving informed consent.
  • Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (28)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
AusperBio Investigational Site
Coordinator of this site? Confirm its status
BeijingChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
ChangchunChinaRecruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
ChanghouChinaRecruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
ChangshaChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
ChengduChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
ChongqingChinaRecruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
FoshanChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
FuzhouChinaRecruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
GuangzhouChinaRecruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
HaikouChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
HangzhouChinaRecruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
HefeiChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
KunmingChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
LanzhouChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
LiuzhouChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
NanchangChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
NanjingChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
NanningChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
ShanghaiChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
ShenyangChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
ShenzhenChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
TaiyuanChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
WuhanChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
XiamenChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
Xi’anChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
ZhengzhouChinaNot yet recruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
ZhenjiangChinaRecruiting
AusperBio Investigational Site
Coordinator of this site? Confirm its status
ZunyiChinaNot yet recruiting

This page is information, not medical advice. Discuss any trial with your doctor.